News Image

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.

By Mill Chart

Last update: May 15, 2024

Our stock screener has spotted EXELIXIS INC (NASDAQ:EXEL) as an undervalued stock with solid fundamentals. NASDAQ:EXEL shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

Valuation Assessment of NASDAQ:EXEL

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:EXEL boasts a 8 out of 10:

  • Compared to the rest of the industry, the Price/Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.21% of the companies listed in the same industry.
  • EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.75% of the companies in the same industry.
  • EXEL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 20.31, which is the current average of the S&P500 Index.
  • Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaper than 95.73% of the companies in the same industry.
  • EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXEL is cheaper than 97.78% of the companies in the same industry.
  • EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 46.47% in the coming years.

Profitability Analysis for NASDAQ:EXEL

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:EXEL has earned a 7 out of 10:

  • Looking at the Return On Assets, with a value of 7.31%, EXEL belongs to the top of the industry, outperforming 96.24% of the companies in the same industry.
  • With an excellent Return On Equity value of 9.64%, EXEL belongs to the best of the industry, outperforming 96.07% of the companies in the same industry.
  • The Return On Invested Capital of EXEL (6.66%) is better than 95.56% of its industry peers.
  • EXEL has a Profit Margin of 11.10%. This is amongst the best in the industry. EXEL outperforms 95.73% of its industry peers.
  • The Operating Margin of EXEL (11.07%) is better than 95.04% of its industry peers.
  • Looking at the Gross Margin, with a value of 95.69%, EXEL belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.

Assessing Health Metrics for NASDAQ:EXEL

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has received a 7 out of 10:

  • EXEL has an Altman-Z score of 6.59. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
  • EXEL's Altman-Z score of 6.59 is amongst the best of the industry. EXEL outperforms 82.22% of its industry peers.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • EXEL has a Current Ratio of 3.46. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 3.41 indicates that EXEL has no problem at all paying its short term obligations.

Growth Analysis for NASDAQ:EXEL

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 6 for growth:

  • The Earnings Per Share has grown by an impressive 43.75% over the past year.
  • EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.99%.
  • Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 16.47% on average per year.
  • The Earnings Per Share is expected to grow by 35.60% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 8.17% on average per year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Our latest full fundamental report of EXEL contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

EXELIXIS INC

NASDAQ:EXEL (5/24/2024, 7:25:26 PM)

After market: 20.57 0 (0%)

20.57

+0.16 (+0.78%)

EXEL News

News Image6 days ago - Exelixis, Inc.Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
News Image9 days ago - Market News VideoJuly 19th Options Now Available For Exelixis (EXEL)
News Image11 days ago - ChartmillIn a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

News Image12 days ago - Market News VideoOversold Conditions For Exelixis (EXEL)
News Image14 days ago - The Motley FoolBillionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?

These stocks are both experts in their respective fields.

News Image18 days ago - InvestorPlaceJust Say No to Drugs: 3 Pharma Stocks to Avoid

Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.

News Image19 days ago - Exelixis, Inc.Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
News Image25 days ago - Market News VideoNotable Wednesday Option Activity: TMDX, WRB, EXEL
News Image25 days ago - Market News VideoExelixis (EXEL) Shares Cross Below 200 DMA
News Image26 days ago - The Motley FoolExelixis (EXEL) Q1 2024 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2024.

News Image26 days ago - InvestorPlaceEXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024

EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image26 days ago - BusinessInsiderEXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Exelixis (NASDAQ:EXEL) just reported results for the first quarter of 2024.Exel...

EXEL Links
Follow us for more